# REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

> **NCT04409080** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Severe Aplastic Anemia (SAA)

## Interventions

- **DRUG:** REGN7257

## Key facts

- **NCT ID:** NCT04409080
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-13
- **Primary completion:** 2024-10-17
- **Final completion:** 2024-10-17
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04409080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04409080, "REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04409080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*